Corrections to “Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines”

Ann Oncol 2017; 28: iv100–iv118 (doi:10.1093/annonc/mdx216) In “Table 6. Characteristics and management of IRs with some monoclonal antibodies” (row 6, column 4) 90% on the first infusion. Severe 2%–5% Is replaced with: Incidence of IR 7-10%. Severe IR in 2-5%, 90% of which occur in the first infusion. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice GuidelinesAnnals of OncologyVol. 28PreviewMost anticancer treatments carry a risk for infusion reactions (IRs); incidence may increase when different agents are administered concomitantly. IRs are either allergic reactions to foreign proteins [generally immunoglobulin E (IgE)-mediated allergic responses] or non-immune-mediated reactions [1]. Most IRs are mild with symptoms such as chills, fever, nausea, headache, skin rash, pruritus, etc. Severe reactions are less frequent and may be fatal without appropriate intervention. Full-Text PDF Open Archive